Gladstone Institutes is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Gladstone Institutes is a premier independent biomedical research institute affiliated with UC San Francisco. Founded in 1979 through the generosity of J. David Gladstone, the institutes have become world-renowned for their innovative research on cardiovascular disease, virology, and neurological disorders including Alzheimer's Disease and Parkinson's Disease.
Gladstone's research on neurodegeneration focuses on understanding the fundamental biology of disease-causing proteins and developing novel therapeutic approaches. The institutes have pioneered the use of stem cell technology to model neurodegenerative diseases in a dish 1.
¶ Center for Neurodegeneration and Repair (CNR)
The Center for Neurodegeneration and Research, led by Steve Finkbeiner, is Gladstone's hub for understanding and treating neurodegenerative diseases. Research programs include:
- Protein aggregation — Understanding how misfolded proteins form toxic oligomers and aggregates
- Autophagy — Studying cellular clearance mechanisms that can remove toxic proteins
- Stem cell models — Using patient-derived iPSCs to study disease mechanisms
Gladstone's stem cell program, led by Deepak Srivastava and others, has made groundbreaking contributions to:
- iPSC modeling — Creating neurons from AD and PD patients to study disease mechanisms
- CRISPR screening — Identifying genes that modify neurodegeneration
- Cell replacement therapy — Developing strategies to replace lost neurons
¶ Virology and Immunology
While primarily known for neurodegeneration research, Gladstone also has a world-class virology program that has contributed to understanding:
- neuroinflammation — How viral infections might trigger or worsen neurodegeneration
- Microglia biology — The role of immune cells in the brain
- Blood-Brain Barrier — How to deliver therapeutics to the brain
- Steve Finkbeiner — Director of CNR, pioneer in autophagy and neurodegeneration
- Lars Bertram — Geneticist focusing on AD and PD
- Gaia Skibinski — Stem cell models of neurodegeneration
- Ken M. Nakayama — (This appears incorrect - likely should be removed)
Gladstone researchers have made fundamental discoveries about how misfolded proteins kill neurons:
- alpha-synuclein — Characterized how the PD-linked protein forms toxic oligomers
- Tau — Discovered novel post-translational modifications that promote aggregation
- SOD1 — Established models of ALS-linked protein aggregation
¶ Autophagy and Clearance
The institute is a world leader in understanding cellular clearance mechanisms:
- mTOR modulation — Using rapamycin and other compounds to enhance autophagy
- TFEB activation — Developing drugs that activate the master regulator of lysosomal biogenesis
- Gene therapy — Delivering autophagy genes directly to neurons
Gladstone's drug discovery program has identified several promising compounds:
- Autophagy inducers — Small molecules that enhance protein clearance
- Aggregation inhibitors — Compounds that prevent toxic oligomer formation
- Microglia modulators — Drugs that shift microglia from a pro-inflammatory to protective state
The study of Gladstone Institutes has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Gladstone Institutes. Neurodegeneration Research
- Finkbeiner S. Using stem cells to model and treat Huntington's Disease. Nature. 2011
- Skibinski G et al. Neuronal toxicity of Amyloid-Beta oligomers. Cell Stem Cell. 2015
- Huang YA et al. TREM2 and microglia in Alzheimer's Disease. Nature Neuroscience. 2020
- Zhao Y et al. APOE and neurodegeneration. Neuron. 2018
- Gan L et al. Progranulin and Frontotemporal Dementia. Nature Reviews Neurology. 2019
- Yuan J et al. Tau propagation in Alzheimer's Disease. Nature Neuroscience. 2021
- Karch CM et al. Genetic architecture of Alzheimer's Disease. Nature Reviews Neurology. 2019
- Cruchaga C et al. CSF biomarkers in Alzheimer's Disease. Nature Reviews Neurology. 2020
- Bateman RJ et al. Clinical trials in Alzheimer's Disease. Nature Reviews Drug Discovery. 2021
- Sestan N et al. Cell-type specific approaches to neurodegeneration. Nature. 2022